Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 20/20 | 0.48 |
| ▸ | RXRG | P48443 | 15/20 | 0.48 |
| ▸ | RARB | P10826 | 7/20 | 0.48 |
| ▸ | RARG | P13631 | 6/20 | 0.48 |
| ▸ | RARA | P10276 | 3/20 | 0.48 |
| ▸ | RXRB | P28702 | 11/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8309204 | 1.00 | RXRA (0.48) | RXRARXRGRARBRARGRARA | |
| SCHEMBL8524314 | 0.83 | RXRA (0.32) | RXRARXRGRARBRARGRARA | |
| SCHEMBL6037057 | 0.81 | RXRA (0.52) | RXRARXRGRARBRARGRARA | |
| SCHEMBL6037055 | 0.81 | RXRA (0.52) | RXRARXRGRARBRARGRARA | |
| SCHEMBL6037042 | 0.77 | RXRA (0.52) | RXRARXRGRARBRARGRARA | |
| SCHEMBL6037041 | 0.77 | RXRA (0.52) | RXRARXRGRARBRARGRARA | |
| SCHEMBL8309443 | 0.72 | RXRA (0.47) | RXRARXRGRARBRARGRARA | |
| SCHEMBL8309439 | 0.72 | RXRA (0.47) | RXRARXRGRARBRARGRARA | |
| SCHEMBL8309188 | 0.70 | RXRA (0.47) | RXRARXRGRARBRARGRARA | |
| SCHEMBL8309191 | 0.70 | RXRA (0.47) | RXRARXRGRARBRARGRARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0800504-B1 | TRICYCLIC RETINOIDS, METHODS FOR THEIR PRODUCTION AND USE | LIGAND PHARM INC (US) | 1999-12-01 | — | — | EP | claimed |
| EP-0800504-A1 | TRICYCLIC RETINOIDS, METHODS FOR THEIR PRODUCTION AND USE | LIGAND PHARMACEUTICALS, INC. (US) | 1997-10-15 | — | — | EP | claimed |
| WO-1996020914-A1 | TRICYCLIC RETINOIDS, METHODS FOR THEIR PRODUCTION AND USE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-07-11 | — | — | WO | claimed |
| EP-0800504-B1 | TRICYCLIC RETINOIDS, METHODS FOR THEIR PRODUCTION AND USE | LIGAND PHARM INC (US) | 1999-12-01 | — | — | EP | disclosed |
| EP-0933350-A1 | Tricyclic retinoids, methods for their production and use | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0933351-A1 | Tricyclic retinoids, methods for their production and use | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0800504-A1 | TRICYCLIC RETINOIDS, METHODS FOR THEIR PRODUCTION AND USE | LIGAND PHARMACEUTICALS, INC. (US) | 1997-10-15 | — | — | EP | disclosed |
| WO-1996020914-A1 | TRICYCLIC RETINOIDS, METHODS FOR THEIR PRODUCTION AND USE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-07-11 | — | — | WO | disclosed |